Ginsenoside Rg1 provides neuroprotection against blood brain barrier disruption and neurological injury in a rat model of cerebral ischemia/reperfusion through downregulation of aquaporin 4 expression

This publication has 32 references indexed in Scilit:

• Guidelines for the Early Management of Patients With Acute Ischemic Stroke
  Stroke, 2013
• Breaking the Barrier in Stroke: What Should we Know? A Mini-Review
  Current Pharmaceutical Design, 2012
• Antidepressant‐like effects of ginsenoside Rg1 are due to activation of the BDNF signalling pathway and neurogenesis in the hippocampus
  British Journal of Pharmacology, 2012
• Experimental approaches to study functional recovery following cerebral ischemia
  Cellular and Molecular Life Sciences, 2011
• Pharmacology of ginsenosides: a literature review
  Chinese Medicine, 2010
• Neuroprotection for ischemic stroke: Past, present and future
  Neuropharmacology, 2008
• Early blood–brain barrier disruption in human focal brain ischemia
  Annals of Neurology, 2004
• In Vitro Study of the Relationship between the Structure of Ginsenoside and Its Antioxidative or Prooxidative Activity in Free Radical Induced Hemolysis of Human Erythrocytes
  Journal of Agricultural and Food Chemistry, 2003
• Ginsenosides Rb1and Rg3protect cultured rat cortical cells from glutamate-induced neurodegeneration
  Journal of Neuroscience Research, 1998
• Reversible middle cerebral artery occlusion without craniectomy in rats.
  Stroke, 1989